Nouscom Appoints Tiffany Muller as Chief Financial Officer and Loredana Siani as Senior Vice President, Technical and CMC Development
17 Julio 2024 - 2:00AM
BASEL, Switzerland –
17th July 2024 -
Nouscom, a clinical stage immuno-oncology company developing
off-the-shelf and personalized viral vector-based cancer vaccines
targeting neoantigens, today announces the promotion of Tiffany
Muller to Chief Financial Officer (CFO) and Loredana Siani, Ph.D.,
to Senior Vice President (SVP), Technical and CMC Development.
Ms. Muller joined Nouscom in 2019 as Vice President
of Finance bringing close to 20 years of experience in finance,
including global treasury, financial planning and analysis
(FP&A), investments and investor relations. In 2023, she was
promoted to Senior Vice President of Finance. Prior to joining
Nouscom, she held various leadership roles at Aramark, a
Nasdaq-listed company, managing complex financial operations,
including debt issuances, large hedge portfolios, and investor
relationships. She holds a B.A. and an M.A. in Mathematics from
Bryn Mawr College, Pennsylvania, and Villanova University,
Pennsylvania respectively. Ms. Muller is based in the US.
Dr. Siani joined Nouscom as Technical Director in
2020 from Reithera, a contract development and manufacturing
organization (CDMO), where she served as the GMP Manufacturing
Head. Previously, she held the same role at Advent GMP Facility
(now Advaxia Biologics). In these positions, Loredana was
instrumental in getting CDMO manufacturing authorizations and
successfully oversaw multiple end-to-end production campaigns for
viral vector products used both in gene therapy and vaccines. She
has a Ph.D. in Industrial Biotechnology Science from the University
Federico II in Naples and an executive MBA from Luiss Business
School in Rome, Italy.
Dr. Marina Udier, CEO of Nouscom,
commented: “Tiffany is a highly valued leader and strategic thought
partner who has been instrumental to Nouscom’s recent successful
oversubscribed series C financing and overall corporate
development. We are thrilled to promote Tiffany to CFO at this
pivotal time as we advance our clinical cancer vaccine portfolio to
late-stage development. Her extensive experience and demonstrated
capability, along with our robust financial standing, position
Nouscom to accelerate its growth and build on the successes
achieved to date.
“Simultaneously, Loredana will be stepping into the
important role of Senior Vice President of Technical and CMC
Development. With her extensive expertise and collaborative spirit,
Loredana has been an integral part of our team, consistently
exceeding expectations to ensure Nouscom’s success. Her ability to
inspire others has made a significant positive impact on our team
and will be crucial as we prepare for the next stage in the
company’s growth.
“The combined experience and proven leadership
brought by Tiffany and Loredana in their respective fields will be
instrumental as we advance our neo-antigen cancer vaccine pipeline,
including NOUS-209 for cancer interception in Lynch Syndrome
carriers. This is a critical moment for Nouscom as we evolve into a
late-stage development company.”
Tiffany Muller, CFO of Nouscom,
added: “I am honored to step into the role of CFO at Nouscom. This
is an exciting time for the Company, and I look forward to
continuing collaboration with this excellent team to drive
Nouscom’s growth and business strategies forward. Together we are
committed to deliver on our goals of advancing our pipeline of
transformative cancer vaccines to patients.”
Dr. Loredana Siani, SVP, Technical and CMC
Development at Nouscom, said: “I am excited to step into
the role of Senior Vice President, Technical and CMC Development at
this crucial time for Nouscom. I am eager to continue our work with
our exceptional teams to further implement our CMC strategies,
particularly across our clinical-stage portfolio. This function
grows in significance as we advance our programs in the clinic,
including our ongoing randomized Phase 2 trial of NOUS-209 in MSI
colorectal cancer patients, while planning next steps with this
unique asset to intercept cancer in Lynch Syndrome carriers.”
Ends
About Nouscom
Nouscom is a clinical-stage immuno-oncology company
developing next-generation, off-the-shelf and personalized cancer
immunotherapies. Nouscom’s proprietary viral vector platform has
the capacity to encode for large payloads of neoantigens or other
immunomodulators and clinically demonstrated to safely and potently
harness the power of the immune system.
Nouscom is currently advancing the clinical
development of its wholly owned programs:
- NOUS-209, an off-the-shelf cancer
immunotherapy for the treatment of MSI solid tumors in combination
with pembrolizumab in randomized Phase 2 trials.
- NOUS-209, an off-the-shelf
monotherapy in Lynch Syndrome carriers with the potential to
‘intercept cancer’ before it occurs. A Phase 1b is being conducted
under a clinical trial collaboration and supply agreement signed in
2022 with the National Cancer Institute (NCI).
- NOUS-PEV, a personalized cancer
immunotherapy, is expected to enter randomized Phase 2 trials in
indications with high unmet medical need in 2025.
Nouscom has also exclusively out-licensed
VAC-85135, an off-the-shelf immunotherapy developed under a
multi-project agreement, which is currently under evaluation in a
Phase 1 trial for the treatment of Myeloproliferative Neoplasms
sponsored by Janssen Research & Development and Bristol Myers
Squibb.
For more information on Nouscom, please visit the
company’s website at www.nouscom.com or follow us on LinkedIn.
Contacts
NouscomRick Davis, COOE : info@nouscom.com T
: +41 61 201 1835 |
MEDiSTRAVA Sylvie Berrebi, Mark Swallow E :
nouscom@medistrava.comT : +44 (0)203 928 6900 |